These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

260 related articles for article (PubMed ID: 17161351)

  • 1. Immunosuppression based on mycophenolate mofetil in stable liver transplanted patients.
    Bilbao I; Castells L; Rojas L; Cancino J; Dopazo C; Castro E; Pou L; Andino R; Margarit C
    Int Immunopharmacol; 2006 Dec; 6(13-14):1977-83. PubMed ID: 17161351
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Conversion from calcineurin inhibitor to either mycophenolate mofetil or sirolimus improves renal function in liver transplant recipients with chronic kidney disease: results of a prospective randomized trial.
    Herlenius G; Felldin M; Nordén G; Olausson M; Bäckman L; Gustafsson B; Friman S
    Transplant Proc; 2010 Dec; 42(10):4441-8. PubMed ID: 21168715
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term mycophenolate mofetil monotherapy in combination with calcineurin inhibitors for chronic renal dysfunction after liver transplantation.
    Raimondo ML; Dagher L; Papatheodoridis GV; Rolando N; Patch DW; Davidson BR; Rolles K; Burroughs AK
    Transplantation; 2003 Jan; 75(2):186-90. PubMed ID: 12548120
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term effects of calcineurin inhibitor conversion to mycophenolate mofetil on renal function after liver transplantation.
    Créput C; Blandin F; Deroure B; Roche B; Saliba F; Charpentier B; Samuel D; Durrbach A
    Liver Transpl; 2007 Jul; 13(7):1004-10. PubMed ID: 17600361
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of mycophenolate mofetil monotherapy in liver transplant patients with renal failure induced by calcineurin inhibitors.
    Barrera Pulido L; Alamo Martínez JM; Pareja Ciuró F; Gómez Bravo MA; Serrano Díez-Canedo J; Bernal Bellido C; Suárez Artacho G; García González I; Pascasio Acevedo JM; Bernardos Rodríguez A
    Transplant Proc; 2008 Nov; 40(9):2985-7. PubMed ID: 19010168
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sustained renal response to mycophenolate mofetil and CNI taper promotes survival in liver transplant patients with CNI-related renal dysfunction.
    Kornberg A; Küpper B; Thrum K; Krause B; Büchler P; Kornberg J; Sappler A; Altendorf-Hofmann A; Wilberg J; Friess H
    Dig Dis Sci; 2011 Jan; 56(1):244-51. PubMed ID: 20824504
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mycophenolate mofetil monotherapy in patients who underwent liver transplantation for hepatitis C cirrhosis.
    Manrique A; Jiménez C; Ortega P; Abradelo M; Gimeno A; Calvo J; Cambra F; -Sterup RL; Morales JM; Moreno E
    Transplant Proc; 2008 Nov; 40(9):2962-4. PubMed ID: 19010160
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Renal recovery after conversion to a calcineurin inhibitor-free immunosuppression in late cardiac transplant recipients.
    Groetzner J; Kaczmarek I; Landwehr P; Mueller M; Daebritz S; Lamm P; Meiser B; Reichart B
    Eur J Cardiothorac Surg; 2004 Mar; 25(3):333-41. PubMed ID: 15019657
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Conversion from calcineurin inhibitor to mycophenolate mofetil-based immunosuppression changes the frequency and phenotype of CD4+FOXP3+ regulatory T cells.
    Demirkiran A; Sewgobind VD; van der Weijde J; Kok A; Baan CC; Kwekkeboom J; Tilanus HW; Metselaar HJ; van der Laan LJ
    Transplantation; 2009 Apr; 87(7):1062-8. PubMed ID: 19352129
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mycophenolate mofetil in combination with reduction of calcineurin inhibitors for chronic renal dysfunction after liver transplantation.
    Pageaux GP; Rostaing L; Calmus Y; Duvoux C; Vanlemmens C; Hardgwissen J; Bernard PH; Barbotte E; Vercambre L; Bismuth M; Puche P; Navarro F; Larrey D
    Liver Transpl; 2006 Dec; 12(12):1755-60. PubMed ID: 17133564
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Conversion of liver transplant recipients on cyclosporine with renal impairment to mycophenolate mofetil.
    Herrero JI; Quiroga J; Sangro B; Girala M; Gómez-Manero N; Pardo F; Alvárez-Cienfuegos J; Prieto J
    Liver Transpl Surg; 1999 Sep; 5(5):414-20. PubMed ID: 10477843
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mycophenolate mofetil monotherapy in liver transplant recipients.
    Kriss M; Sotil EU; Abecassis M; Welti M; Levitsky J
    Clin Transplant; 2011; 25(6):E639-46. PubMed ID: 22007615
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combined mycophenolate mofetil and minimal dose calcineurin inhibitor therapy in liver transplant patients: clinical results of a prospective randomized study.
    Beckebaum S; Klein CG; Sotiropoulos GC; Saner FH; Gerken G; Paul A; Cicinnati VR
    Transplant Proc; 2009; 41(6):2567-9. PubMed ID: 19715976
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mycophenolate mofetil in liver transplant patients with calcineurin-inhibitor-induced renal impairment.
    Ko HH; Greanya E; Lee TK; Steinbrecher UP; Erb SR; Yoshida EM
    Ann Hepatol; 2008; 7(4):376-80. PubMed ID: 19034239
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mycophenolate and sirolimus as calcineurin inhibitor-free immunosuppression improves renal function better than calcineurin inhibitor-reduction in late cardiac transplant recipients with chronic renal failure.
    Groetzner J; Kaczmarek I; Schulz U; Stegemann E; Kaiser K; Wittwer T; Schirmer J; Voss M; Strauch J; Wahlers T; Sohn HY; Wagner F; Tenderich G; Stempfle HU; Mueller-Ehmsen J; Schmid C; Vogeser M; Koch KC; Reichenspurner H; Daebritz S; Meiser B; Reichart B;
    Transplantation; 2009 Mar; 87(5):726-33. PubMed ID: 19295318
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Improvement of renal function after conversion to mycophenolate mofetil combined with low-level calcineurin inhibitor in liver transplant recipients with chronic renal dysfunction.
    Ponton C; Vizcaíno L; Tomé S; Otero E; Molina E; Castroagudín JF; López-Lago A; Varo Pérez E
    Transplant Proc; 2010 Mar; 42(2):656-9. PubMed ID: 20304216
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Calcineurin inhibitor-free mycophenolate mofetil/sirolimus maintenance in liver transplantation: the randomized spare-the-nephron trial.
    Teperman L; Moonka D; Sebastian A; Sher L; Marotta P; Marsh C; Koneru B; Goss J; Preston D; Roberts JP;
    Liver Transpl; 2013 Jul; 19(7):675-89. PubMed ID: 23775875
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Conversion from calcineurin inhibitors to sirolimus of recipients with chronic kidney graft disease grade III for a period 2003-2011.
    Ignjatović L; Hrvacević R; Jovanović D; Kovacević Z; Vavić N; Rabrenović V; Tomić A; Aleksić P; Drasković-Pavlović B; Dujić A; Karan Z; Maksić D
    Vojnosanit Pregl; 2013 Sep; 70(9):848-53. PubMed ID: 24266313
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mycophenolate mofetil and sirolimus as calcineurin inhibitor-free immunosuppression for late cardiac-transplant recipients with chronic renal failure.
    Groetzner J; Meiser B; Landwehr P; Buehse L; Mueller M; Kaczmarek I; Vogeser M; Daebritz S; Ueberfuhr P; Reichart B
    Transplantation; 2004 Feb; 77(4):568-74. PubMed ID: 15084937
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Calcineurin-inhibitor-sparing immunosuppressive protocols.
    Bestard O; Cruzado JM; Grinyó JM
    Transplant Proc; 2005 Nov; 37(9):3729-32. PubMed ID: 16386520
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.